{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:26Z","timestamp":1786979966318,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-024-05735-w","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:01:42Z","timestamp":1728432102000},"page":"3127-3133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Successful treatment of Crohn\u2019s disease-related peripheral spondyloarthritis with upadacitinib: two case reports and case-based review"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1358-7069","authenticated-orcid":false,"given":"Koji","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5075-8977","authenticated-orcid":false,"given":"Mitsuhiro","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Inokuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironari","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-5765","authenticated-orcid":false,"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"5735_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","volume":"10","author":"M Harbord","year":"2016","unstructured":"Harbord M, Annese V, Vavricka SR et al (2016) The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 10:239\u2013254. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv213","journal-title":"J Crohns Colitis"},{"key":"5735_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R et al (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25\u201331. https:\/\/doi.org\/10.1136\/ard.2010.133645","journal-title":"Ann Rheum Dis"},{"key":"5735_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/gut.42.3.387","volume":"42","author":"TR Orchard","year":"1998","unstructured":"Orchard TR, Wordsworth BP, Jewell DP (1998) Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 42:387\u2013391. https:\/\/doi.org\/10.1136\/gut.42.3.387","journal-title":"Gut"},{"key":"5735_CR4","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/s0140-6736(00)03239-6","volume":"356","author":"F Van den Bosch","year":"2000","unstructured":"Van den Bosch F, Kruithof E, De Vos M et al (2000) Crohn\u2019s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 356:1821\u20131822. https:\/\/doi.org\/10.1016\/s0140-6736(00)03239-6","journal-title":"Lancet"},{"key":"5735_CR5","doi-asserted-by":"publisher","first-page":"e001697","DOI":"10.1136\/rmdopen-2021-001697","volume":"8","author":"L Cachen","year":"2022","unstructured":"Cachen L, Nocturne G, Collins M et al (2022) Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF. RMD Open 8:e001697. https:\/\/doi.org\/10.1136\/rmdopen-2021-001697","journal-title":"RMD Open"},{"key":"5735_CR6","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr, Pan\u00e9s J, Lacerda AP et al (2023) Upadacitinib induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med 388:1966\u20131980. https:\/\/doi.org\/10.1056\/NEJMoa2212728","journal-title":"N Engl J Med"},{"key":"5735_CR7","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/ard-2022-222608","volume":"81","author":"D van der Heijde","year":"2022","unstructured":"van der Heijde D, Baraliakos X, Sieper J et al (2022) Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis 81:1515\u20131523. https:\/\/doi.org\/10.1136\/ard-2022-222608","journal-title":"Ann Rheum Dis"},{"key":"5735_CR8","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409\u20131417. https:\/\/doi.org\/10.1007\/s00296-011-1999-3","journal-title":"Rheumatol Int"},{"key":"5735_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13256-023-03796-2","volume":"17","author":"MS Momen Majumder","year":"2023","unstructured":"Momen Majumder MS, Haq SA, Rasker JJ (2023) Tofacitinib for the treatment of inflammatory bowel disease-associated arthritis: two case reports. J Med Case Rep 17:71. https:\/\/doi.org\/10.1186\/s13256-023-03796-2","journal-title":"J Med Case Rep"},{"key":"5735_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00535-012-0673-1","volume":"48","author":"F Ueno","year":"2013","unstructured":"Ueno F, Matsui T, Matsumoto T et al (2013) Evidence-based clinical practice guidelines for Crohn\u2019s disease, integrated with formal consensus of experts in Japan. J Gastroenterol 48:31\u201372. https:\/\/doi.org\/10.1007\/s00535-012-0673-1","journal-title":"J Gastroenterol"},{"key":"5735_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ard.2008.094870","volume":"68","author":"C Lukas","year":"2009","unstructured":"Lukas C, Landew\u00e9 R, Sieper J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68:18\u201324. https:\/\/doi.org\/10.1136\/ard.2008.094870","journal-title":"Ann Rheum Dis"},{"key":"5735_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41584-023-00984-8","volume":"19","author":"G Cozzi","year":"2023","unstructured":"Cozzi G, Scagnellato L, Lorenzin M et al (2023) Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies. Nat Rev Rheumatol 19:503\u2013518. https:\/\/doi.org\/10.1038\/s41584-023-00984-8","journal-title":"Nat Rev Rheumatol"},{"key":"5735_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00132-2","author":"K Song","year":"2024","unstructured":"Song K, Satsangi J, Coates LC (2024) Arthritis complicating inflammatory bowel disease- the future is now. Lancet Rheumatol. https:\/\/doi.org\/10.1016\/S2665-9913(24)00132-2","journal-title":"Lancet Rheumatol"},{"key":"5735_CR14","doi-asserted-by":"publisher","first-page":"175628482110599","DOI":"10.1177\/17562848211059954","volume":"14","author":"L Peyrin-Biroulet","year":"2021","unstructured":"Peyrin-Biroulet L, Sandborn WJ, Panaccione R et al (2021) Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Th Adv Gastroenterol 14:17562848211059954. https:\/\/doi.org\/10.1177\/17562848211059954","journal-title":"Th Adv Gastroenterol"},{"key":"5735_CR15","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/art.24389","volume":"60","author":"F Ciccia","year":"2009","unstructured":"Ciccia F, Bombardieri M, Principato A et al (2009) Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum 60:955\u2013965. https:\/\/doi.org\/10.1002\/art.24389","journal-title":"Arthritis Rheum"},{"key":"5735_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/imr.12840","volume":"294","author":"C Bridgewood","year":"2020","unstructured":"Bridgewood C, Sharif K, Sherlock J et al (2020) Interleukin-23 pathway at the enthesis: the emerging story of enthesitis in spondyloarthropathy. Immunol Rev 294:27\u201347. https:\/\/doi.org\/10.1111\/imr.12840","journal-title":"Immunol Rev"},{"key":"5735_CR17","doi-asserted-by":"publisher","first-page":"6401","DOI":"10.3390\/ijms21176401","volume":"21","author":"H Tsukazaki","year":"2020","unstructured":"Tsukazaki H, Kaito T (2020) The role of the IL-23\/IL-17 pathway in the pathogenesis of spondyloarthritis. Int J Mol Sci 21:6401. https:\/\/doi.org\/10.3390\/ijms21176401","journal-title":"Int J Mol Sci"},{"key":"5735_CR18","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00011-014-0768-7","volume":"63","author":"W Jiang","year":"2014","unstructured":"Jiang W, Su J, Zhang X et al (2014) Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease. Inflamm Res 63:943\u2013950. https:\/\/doi.org\/10.1007\/s00011-014-0768-7","journal-title":"Inflamm Res"},{"key":"5735_CR19","first-page":"1085","volume":"34","author":"P Triggianese","year":"2016","unstructured":"Triggianese P, Conigliaro P, Chimenti M et al (2016) Evidence of IL-17 producing innate lymphoid cells in peripheral blood from patients with enteropathic spondyloarthritis. Clin Exp Rheumatol 34:1085\u20131093","journal-title":"Clin Exp Rheumatol"},{"key":"5735_CR20","doi-asserted-by":"publisher","unstructured":"Viladomiu M, Kivolowitz C, Abdulhamid A et al (2017) IgA-coated E. Coli enriched in Crohn\u2019s disease spondyloarthritis promote TH17-dependent inflammation. Sci Transl Med 9. https:\/\/doi.org\/10.1126\/scitranslmed.aaf9655","DOI":"10.1126\/scitranslmed.aaf9655"},{"key":"5735_CR21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Gensler LS, Sieper J et al (2019) Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol 71:258\u2013270. https:\/\/doi.org\/10.1002\/art.40728","journal-title":"Arthritis Rheumatol"},{"key":"5735_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/oarrr.s263259","volume":"12","author":"S Matsumoto","year":"2020","unstructured":"Matsumoto S, Matsumoto K, Takaya H et al (2020) Efficacy of Ustekinumab Against Spondyloarthritis Associated with Crohn\u2019s Disease: a Case Report and Review of the literature. Open Access Rheumatol 12:133\u2013137. https:\/\/doi.org\/10.2147\/oarrr.s263259","journal-title":"Open Access Rheumatol"},{"key":"5735_CR23","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1080\/14712598.2020.1830057","volume":"20","author":"FS Macaluso","year":"2020","unstructured":"Macaluso FS, Fries W, Viola A et al (2020) Effectiveness of Ustekinumab on Crohn\u2019s disease associated spondyloarthropathy: real-world data from the Sicilian Network for Inflammatory Bowel diseases (SN-IBD). Expert Opin Biol Ther 20:1381\u20131384. https:\/\/doi.org\/10.1080\/14712598.2020.1830057","journal-title":"Expert Opin Biol Ther"},{"key":"5735_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40744-021-00400-1","volume":"9","author":"M Aparicio","year":"2022","unstructured":"Aparicio M, Guill\u00e9n-Astete CA, L\u00f3pez-Medina C et al (2022) Evidence for the use of secukinumab in patients with radiographic and non-radiographic axial spondyloarthritis in the last 5 years. Rheumatol Ther 9:73\u201394. https:\/\/doi.org\/10.1007\/s40744-021-00400-1","journal-title":"Rheumatol Ther"},{"key":"5735_CR25","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S et al (2012) Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61:1693\u20131700. https:\/\/doi.org\/10.1136\/gutjnl-2011-301668","journal-title":"Gut"},{"key":"5735_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/cpt.2155","volume":"110","author":"N Petitpain","year":"2021","unstructured":"Petitpain N, D\u2019Amico F, Yelehe-Okouma M et al (2021) IL-17 inhibitors and inflammatory bowel diseases: a postmarketing study in Vigibase. Clin Pharmacol Ther 110:159\u2013168. https:\/\/doi.org\/10.1002\/cpt.2155","journal-title":"Clin Pharmacol Ther"},{"key":"5735_CR27","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/rheumatology\/keab740","volume":"61","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Szekanecz Z, McGonagle D et al (2022) A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. Rheumatology (Oxford) 61:1783\u20131794. https:\/\/doi.org\/10.1093\/rheumatology\/keab740","journal-title":"Rheumatology (Oxford)"},{"key":"5735_CR28","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","volume":"80","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Sliwinska-Stanczyk P, Xu H et al (2021) Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 80:1004\u20131013. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219601","journal-title":"Ann Rheum Dis"},{"key":"5735_CR29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","volume":"66","author":"J Pan\u00e9s","year":"2017","unstructured":"Pan\u00e9s J, Sandborn WJ, Schreiber S et al (2017) Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials. Gut 66:1049\u20131059. https:\/\/doi.org\/10.1136\/gutjnl-2016-312735","journal-title":"Gut"},{"key":"5735_CR30","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1093\/ibd\/izab116","volume":"27","author":"D Aguilar","year":"2021","unstructured":"Aguilar D, Revilla L, Garrido-Trigo A et al (2021) Randomized controlled trial substudy of cell-specific mechanisms of Janus kinase 1 inhibition with upadacitinib in the Crohn\u2019s disease intestinal mucosa: analysis from the CELEST study. Inflamm Bowel Dis 27:1999\u20132009. https:\/\/doi.org\/10.1093\/ibd\/izab116","journal-title":"Inflamm Bowel Dis"},{"key":"5735_CR31","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","volume":"80","author":"PG Traves","year":"2021","unstructured":"Traves PG, Murray B, Campigotto F et al (2021) JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis 80:865\u2013875. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219012","journal-title":"Ann Rheum Dis"},{"key":"5735_CR32","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/14656566.2024.2333964","volume":"25","author":"A Dignass","year":"2024","unstructured":"Dignass A, Esters P, Flauaus C (2024) Upadacitinib in Crohn\u2019s disease. Expert Opin Pharmacother 25:359\u2013370. https:\/\/doi.org\/10.1080\/14656566.2024.2333964","journal-title":"Expert Opin Pharmacother"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05735-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-024-05735-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05735-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T11:05:57Z","timestamp":1733310357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-024-05735-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5735"],"URL":"https:\/\/doi.org\/10.1007\/s00296-024-05735-w","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"assertion":[{"value":"7 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of this report was obtained from the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}